Temat: "Erlotinib Hydrochloride" - OpacWWW

Skocz do pozycji: 1.

Tytuł:: Monolayer culture alters EGFR inhibitor response through abrogation of microRNA-mediated feedback regulation.
Autorzy:: Florio A; Biomarker Discovery Laboratory, Center for Individualized Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.; Mayo Clinic Graduate School of Biomedical Sciences, Rochester, MN, USA.; Department of Molecular Medicine, Mayo Clinic, Rochester, MN, USA.
Johnson S; Biomarker Discovery Laboratory, Center for Individualized Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
Salvatori R; Biomarker Discovery Laboratory, Center for Individualized Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.; Department of Molecular Medicine, Mayo Clinic, Rochester, MN, USA.; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Vasmatzis G; Biomarker Discovery Laboratory, Center for Individualized Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. .; Department of Molecular Medicine, Mayo Clinic, Rochester, MN, USA. .; Pokaż więcej
Źródło:: Scientific reports [Sci Rep] 2024 Mar 27; Vol. 14 (1), pp. 7303. Date of Electronic Publication: 2024 Mar 27.
Typ publikacji:: Journal Article
MeSH Terms:: MicroRNAs*/metabolism
Carcinoma, Non-Small-Cell Lung*/drug therapy
Carcinoma, Non-Small-Cell Lung*/genetics
Carcinoma, Non-Small-Cell Lung*/pathology
Lung Neoplasms*/drug therapy
Lung Neoplasms*/genetics
Lung Neoplasms*/pathology
Antineoplastic Agents*/pharmacology
Adenocarcinoma of Lung*/drug therapy
Adenocarcinoma of Lung*/genetics
Humans ; Erlotinib Hydrochloride/pharmacology ; Erlotinib Hydrochloride/therapeutic use ; Feedback ; ErbB Receptors/metabolism ; Cell Line, Tumor ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/therapeutic use ; Drug Resistance, Neoplasm ; Mutation

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 2.

Tytuł:: Activation of the PI3K/AKT signaling pathway by ARNTL2 enhances cellular glycolysis and sensitizes pancreatic adenocarcinoma to erlotinib.
Autorzy:: Ge W; Department of Oncology and State Key Laboratory of Systems Medicine for Cancer of Shanghai Cancer Institute, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200127, China.; Department of Medical Oncology, Shanghai Medical College, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, 200032, People's Republic of China.
Wang Y; Department of Oncology and State Key Laboratory of Systems Medicine for Cancer of Shanghai Cancer Institute, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200127, China.
Quan M; Department of Oncology and Tumor Institute, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China. .
Mao T; Department of Oncology and State Key Laboratory of Systems Medicine for Cancer of Shanghai Cancer Institute, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200127, China.
Bischof EY; Department of Oncology and State Key Laboratory of Systems Medicine for Cancer of Shanghai Cancer Institute, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200127, China.
Xu H; Department of Oncology and State Key Laboratory of Systems Medicine for Cancer of Shanghai Cancer Institute, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200127, China.
Zhang X; Department of Oncology and State Key Laboratory of Systems Medicine for Cancer of Shanghai Cancer Institute, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200127, China.
Li S; Department of Oncology and State Key Laboratory of Systems Medicine for Cancer of Shanghai Cancer Institute, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200127, China.
Yue M; Department of Oncology and State Key Laboratory of Systems Medicine for Cancer of Shanghai Cancer Institute, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200127, China.
Ma J; Department of Oncology and State Key Laboratory of Systems Medicine for Cancer of Shanghai Cancer Institute, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200127, China.
Yang H; Department of Oncology and State Key Laboratory of Systems Medicine for Cancer of Shanghai Cancer Institute, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200127, China.
Wang L; Department of Oncology, The Affiliated Lianyungang Hospital of Xuzhou Medical University, The First People's Hospital of Lianyungang, Jiangsu, China.
Yu Z; Department of Medical Oncology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China. .
Wang L; Department of Oncology and State Key Laboratory of Systems Medicine for Cancer of Shanghai Cancer Institute, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200127, China. .
Cui J; Department of Oncology and State Key Laboratory of Systems Medicine for Cancer of Shanghai Cancer Institute, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200127, China. .; Pokaż więcej
Źródło:: Molecular cancer [Mol Cancer] 2024 Mar 08; Vol. 23 (1), pp. 48. Date of Electronic Publication: 2024 Mar 08.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Adenocarcinoma*/drug therapy
Adenocarcinoma*/genetics
Lung Neoplasms*/pathology
Pancreatic Neoplasms*/drug therapy
Pancreatic Neoplasms*/genetics
Pancreatic Neoplasms*/pathology
Humans ; ARNTL Transcription Factors/metabolism ; Biomarkers/metabolism ; Cell Line, Tumor ; ErbB Receptors/metabolism ; Erlotinib Hydrochloride/pharmacology ; Phosphatidylinositol 3-Kinases/metabolism ; Phosphorylation ; Precision Medicine ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/therapeutic use ; Proto-Oncogene Proteins c-akt/metabolism ; Signal Transduction

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 3.

Tytuł:: Mechanism of action of adapalene for treating EGFR-TKI-induced skin disorder.
Autorzy:: Mimura C; Division of Respiratory Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
Nagano T; Division of Respiratory Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
Miwa N; Department of Respiratory Medicine, Kobe City Nishi-Kobe Medical Center, Kobe, Japan.
Matsumura K; Department of Respiratory Medicine, Takatsuki General Hospital, Takatsuki, Japan.
Yamada J; Division of Respiratory Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
Satoh H; Division of Respiratory Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
Suraya R; Division of Respiratory Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
Hazama D; Division of Respiratory Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
Tamura D; Tamura Clinic, Takarazuka, Japan.
Yamamoto M; Division of Respiratory Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
Tachihara M; Division of Respiratory Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
Nishimura Y; Department of Respiratory Medicine, Kitaharima Medical Center, Ono, Japan.
Kobayashi K; Division of Respiratory Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.; Pokaż więcej
Źródło:: Thoracic cancer [Thorac Cancer] 2024 Mar; Vol. 15 (9), pp. 722-729. Date of Electronic Publication: 2024 Feb 20.
Typ publikacji:: Journal Article
MeSH Terms:: Skin Diseases*/chemically induced
Lung Neoplasms*/pathology
Humans ; Animals ; Mice ; Afatinib/therapeutic use ; Erlotinib Hydrochloride/adverse effects ; Adapalene/therapeutic use ; ErbB Receptors/metabolism ; Inflammation/chemically induced ; Protein Kinase Inhibitors/adverse effects

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 4.

Tytuł:: Pancreatic adenocarcinoma third line systemic treatments: a retrospective cohort study.
Autorzy:: Gueiderikh A; Département de médecine oncologique, Gustave Roussy, 94800, Villejuif, France.; Université Paris Saclay, 91471, Orsay, France.
Tarabay A; Département de médecine oncologique, Gustave Roussy, 94800, Villejuif, France.
Abdelouahab M; Département de statistiques, Gustave Roussy, 94800, Villejuif, France.
Smolenschi C; Département de médecine oncologique, Gustave Roussy, 94800, Villejuif, France.; Gustave Roussy, DITEP, 94800, Villejuif, France.
Tanguy ML; Département de statistiques, Gustave Roussy, 94800, Villejuif, France.
Valery M; Département de médecine oncologique, Gustave Roussy, 94800, Villejuif, France.
Malka D; Département d'oncologie médicale, Institut Mutualiste Montsouris, 75014, Paris, France.
Pudlarz T; Département de médecine oncologique, Gustave Roussy, 94800, Villejuif, France.
Fuerea A; Département de médecine oncologique, Gustave Roussy, 94800, Villejuif, France.
Boige V; Département de médecine oncologique, Gustave Roussy, 94800, Villejuif, France.
Hollebecque A; Département de médecine oncologique, Gustave Roussy, 94800, Villejuif, France.; Gustave Roussy, DITEP, 94800, Villejuif, France.
Ducreux M; Département de médecine oncologique, Gustave Roussy, 94800, Villejuif, France.; Université Paris Saclay, 91471, Orsay, France.
Boilève A; Département de médecine oncologique, Gustave Roussy, 94800, Villejuif, France. .; Université Paris Saclay, 91471, Orsay, France. .; Pokaż więcej
Źródło:: BMC cancer [BMC Cancer] 2024 Feb 26; Vol. 24 (1), pp. 272. Date of Electronic Publication: 2024 Feb 26.
Typ publikacji:: Journal Article
MeSH Terms:: Pancreatic Neoplasms*/pathology
Adenocarcinoma*/pathology
Humans ; Gemcitabine ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Retrospective Studies ; Erlotinib Hydrochloride/therapeutic use ; Deoxycytidine ; Fluorouracil ; Leucovorin/therapeutic use ; Paclitaxel ; Albumins

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 5.

Tytuł:: Dendritic cell vaccination in combination with erlotinib in a patient with inoperable lung adenocarcinoma: a case report.
Autorzy:: Kosumi T; Kyushukouseikai Clinic, 1-2-12 Tenjin, Chuo-Ku, Fukuoka-Shi, 810-0001, Japan. .
Kobayashi M; Okazakiyuuai Clinic, 104-1 Azaikeda, Tsutsubaricho, Okazaki-Shi, Aichi-ken, 444-0932, Japan.
Shimodaira S; Department of Regenerative Medicine, Kanazawa Medical University, Kahoku, Ishikawa, 920-0293, Japan.
Sugiyama H; Department of Cancer Immunology, Osaka University Graduate School of Medicine, Suita-City, Osaka, 565-0871, Japan.
Koido S; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Kashiwa Hospital, The Jikei University School of Medicine, 163-1 Kashiwa-Shita, Kashiwa, Chiba, 277-8567, Japan.; Pokaż więcej
Źródło:: Journal of medical case reports [J Med Case Rep] 2024 Feb 10; Vol. 18 (1), pp. 88. Date of Electronic Publication: 2024 Feb 10.
Typ publikacji:: Case Reports; Journal Article
MeSH Terms:: Adenocarcinoma of Lung*/drug therapy
Lung Neoplasms*/drug therapy
Lung Neoplasms*/genetics
Wilms Tumor*
Kidney Neoplasms*/drug therapy
Vaccines*/therapeutic use
Female ; Humans ; Middle Aged ; Erlotinib Hydrochloride/therapeutic use ; Mucin-1/genetics ; Mucin-1/therapeutic use ; WT1 Proteins/genetics ; WT1 Proteins/therapeutic use ; ErbB Receptors/genetics ; ErbB Receptors/therapeutic use ; Vaccination ; Dendritic Cells ; Mutation ; Protein Kinase Inhibitors/therapeutic use

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 6.

Tytuł:: First case report of erlotinib plus ramucirumab treatment for lung carcinosarcoma with EGFR L858R mutation.
Autorzy:: Ishibashi N; Department of Thoracic Surgery, Tohoku Medical and Pharmaceutical University Hospital, Sendai City, Japan.
Tabata T; Department of Thoracic Surgery, Tohoku Medical and Pharmaceutical University Hospital, Sendai City, Japan.
Nonomura R; Department of Thoracic Surgery, Tohoku Medical and Pharmaceutical University Hospital, Sendai City, Japan.
Oshima Y; Department of Thoracic Surgery, Tohoku Medical and Pharmaceutical University Hospital, Sendai City, Japan.
Sasaki T; Department of Thoracic Surgery, Tohoku Medical and Pharmaceutical University Hospital, Sendai City, Japan.
Mitomo H; Department of Thoracic Surgery, Tohoku Medical and Pharmaceutical University Hospital, Sendai City, Japan.
Sugawara T; Department of Thoracic Surgery, Tohoku Medical and Pharmaceutical University Hospital, Sendai City, Japan.
Sagawa M; Department of Thoracic Surgery, Tohoku Medical and Pharmaceutical University Hospital, Sendai City, Japan.; Pokaż więcej
Źródło:: Thoracic cancer [Thorac Cancer] 2023 Dec; Vol. 14 (34), pp. 3415-3418. Date of Electronic Publication: 2023 Oct 14.
Typ publikacji:: Case Reports
MeSH Terms:: Carcinoma, Non-Small-Cell Lung*/pathology
Lung Neoplasms*/drug therapy
Lung Neoplasms*/genetics
Lung Neoplasms*/pathology
Aged ; Female ; Humans ; ErbB Receptors/genetics ; Erlotinib Hydrochloride/pharmacology ; Erlotinib Hydrochloride/therapeutic use ; Lung/pathology ; Mutation ; Protein Kinase Inhibitors/therapeutic use ; Ramucirumab

Raport

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 7.

Tytuł:: Design, synthesis, apoptotic, and antiproliferative effects of 5-chloro-3- (2-methoxyvinyl)-indole-2-carboxamides and pyrido[3,4-b]indol-1-ones as potent EGFR inhibitors.
Autorzy:: Al-Wahaibi LH; Department of Chemistry, College of Sciences, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia.
Mohammed AF; Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Assiut University, Assiut, Egypt.
Abdel Rahman FES; Department of Basic Sciences, Faculty of Oral and Dental Medicine, Nahda University, Beni-Suef, Egypt.
Abdelrahman MH; Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Al-Azhar University, Assiut, Egypt.
Gu X; School of Natural and Computing Sciences, University of Aberdeen, Aberdeen, UK.
Trembleau L; School of Natural and Computing Sciences, University of Aberdeen, Aberdeen, UK.
Youssif BGM; Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Assiut University, Assiut, Egypt.; Pokaż więcej
Źródło:: Journal of enzyme inhibition and medicinal chemistry [J Enzyme Inhib Med Chem] 2023 Dec; Vol. 38 (1), pp. 2218602.
Typ publikacji:: Journal Article
MeSH Terms:: Antineoplastic Agents*/chemistry
Lung Neoplasms*/drug therapy
Humans ; ErbB Receptors/metabolism ; Erlotinib Hydrochloride/pharmacology ; Erlotinib Hydrochloride/therapeutic use ; Protein Kinase Inhibitors/chemistry ; Drug Design ; Mutation ; Staurosporine/pharmacology ; Cell Proliferation ; Drug Screening Assays, Antitumor ; Structure-Activity Relationship ; Cell Line, Tumor ; Molecular Docking Simulation ; Molecular Structure

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 8.

Tytuł:: Survival outcomes of east Asian patients with advanced non-small cell lung cancer treated with first-line EGFR tyrosine kinase inhibitors: A network meta-analysis of real-world evidence.
Autorzy:: Chang HC; Divisions of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan.; Ph.D. Program in Environmental and Occupational Medicine, College of Medicine, and Research Center for Precision Environmental Medicine, Kaohsiung Medical University, Kaohsiung City, Taiwan.; Department of Occupational and Environmental Medicine, Kaohsiung Medical University Hospital, Kaohsiung City, Taiwan.
Huang KT; Divisions of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan.
Tseng CC; Divisions of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan.
Chen YM; Divisions of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan.
Lai CH; Divisions of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan.
Chang YP; Divisions of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan.
Chen YC; Divisions of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan.; Department of Respiratory Therapy, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan.
Chuang HY; Ph.D. Program in Environmental and Occupational Medicine, College of Medicine, and Research Center for Precision Environmental Medicine, Kaohsiung Medical University, Kaohsiung City, Taiwan.; Department of Occupational and Environmental Medicine, Kaohsiung Medical University Hospital, Kaohsiung City, Taiwan.
Wang CC; Divisions of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan.; Department of Respiratory Therapy, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan.; Department of Respiratory Care, Chang Gung University of Science and Technology, Chiayi, Taiwan.; Pokaż więcej
Źródło:: Thoracic cancer [Thorac Cancer] 2023 Nov; Vol. 14 (32), pp. 3217-3225. Date of Electronic Publication: 2023 Sep 13.
Typ publikacji:: Meta-Analysis; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Carcinoma, Non-Small-Cell Lung*
Lung Neoplasms*
Adult ; Humans ; Afatinib ; Gefitinib ; Erlotinib Hydrochloride/pharmacology ; Erlotinib Hydrochloride/therapeutic use ; Tyrosine Kinase Inhibitors ; East Asian People ; Network Meta-Analysis ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/therapeutic use ; ErbB Receptors/genetics ; Mutation

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 9.

Tytuł:: Do patient characteristics affect EGFR tyrosine kinase inhibitor treatment outcomes? A network meta-analysis of real-world survival outcomes of East Asian patients with advanced non-small cell lung cancer treated with first-line EGFR-TKIs.
Autorzy:: Chang HC; Divisions of Pulmonary & Critical Care Medicine, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan.; Ph.D. Program in Environmental and Occupational Medicine, College of Medicine, and Research Center for Precision Environmental Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.; Department of Occupational and Environmental Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
Wang CC; Divisions of Pulmonary & Critical Care Medicine, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan.; Department of Respiratory Therapy, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan.; Department of Respiratory Care, Chang Gung University of Science and Technology, Chiayi, Taiwan.
Tseng CC; Divisions of Pulmonary & Critical Care Medicine, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan.
Huang KT; Divisions of Pulmonary & Critical Care Medicine, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan.
Chen YM; Divisions of Pulmonary & Critical Care Medicine, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan.
Chang YP; Divisions of Pulmonary & Critical Care Medicine, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan.
Lai CH; Divisions of Pulmonary & Critical Care Medicine, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan.
Fang WF; Divisions of Pulmonary & Critical Care Medicine, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan.; Department of Respiratory Care, Chang Gung University of Science and Technology, Chiayi, Taiwan.
Lin MC; Divisions of Pulmonary & Critical Care Medicine, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan.; Department of Respiratory Therapy, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan.
Chuang HY; Ph.D. Program in Environmental and Occupational Medicine, College of Medicine, and Research Center for Precision Environmental Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.; Department of Occupational and Environmental Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.; Pokaż więcej
Źródło:: Thoracic cancer [Thorac Cancer] 2023 Nov; Vol. 14 (32), pp. 3208-3216. Date of Electronic Publication: 2023 Sep 22.
Typ publikacji:: Meta-Analysis; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Carcinoma, Non-Small-Cell Lung*/drug therapy
Carcinoma, Non-Small-Cell Lung*/genetics
Carcinoma, Non-Small-Cell Lung*/pathology
Lung Neoplasms*/drug therapy
Lung Neoplasms*/genetics
Lung Neoplasms*/pathology
Brain Neoplasms*/drug therapy
Brain Neoplasms*/genetics
Humans ; Gefitinib/therapeutic use ; Erlotinib Hydrochloride/pharmacology ; Erlotinib Hydrochloride/therapeutic use ; Afatinib/therapeutic use ; Tyrosine Kinase Inhibitors ; East Asian People ; Network Meta-Analysis ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/therapeutic use ; Mutation ; Treatment Outcome ; ErbB Receptors

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 10.

Tytuł:: Hexane Fraction of Adenophora triphylla var. japonica Root Extract Inhibits Angiogenesis and Endothelial Cell-Induced Erlotinib Resistance in Lung Cancer Cells.
Autorzy:: Park HJ; Department of Pathology, College of Korean Medicine, Dong-eui University, Busan 47227, Republic of Korea.
Jeong JH; Department of Pathology, College of Korean Medicine, Dong-eui University, Busan 47227, Republic of Korea.
Choi YH; Department of Biochemistry, College of Korean Medicine, Dong-eui University, Busan 47227, Republic of Korea.
Park SH; Department of Pathology, College of Korean Medicine, Dong-eui University, Busan 47227, Republic of Korea.; Pokaż więcej
Źródło:: Molecules (Basel, Switzerland) [Molecules] 2024 Jan 25; Vol. 29 (3). Date of Electronic Publication: 2024 Jan 25.
Typ publikacji:: Journal Article
MeSH Terms:: Lung Neoplasms*/drug therapy
Lung Neoplasms*/metabolism
Campanulaceae*
Humans ; Erlotinib Hydrochloride/pharmacology ; Vascular Endothelial Growth Factor A/metabolism ; Hexanes/pharmacology ; Angiogenesis ; Angiogenesis Inhibitors/pharmacology ; Human Umbilical Vein Endothelial Cells ; Neovascularization, Pathologic/drug therapy ; Vascular Endothelial Growth Factor Receptor-2 ; Cell Movement ; Cell Proliferation

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 11.

Tytuł:: Secondary metabolites of Trichoderma spp. as EGFR tyrosine kinase inhibitors: Evaluation of anticancer efficacy through computational approach.
Autorzy:: Gowtham HG; Department of PG Studies in Biotechnology, Nrupathunga University, Bangalore, Karnataka, India.
Revanasiddappa PD; Department of Biotechnology, Siddaganga Institute of Technology, Tumkur, India.
Murali M; Department of Studies in Botany, University of Mysore, Mysore, Karnataka, India.
Singh SB; Department of Studies in Botany, University of Mysore, Mysore, Karnataka, India.
Abhilash MR; Department of Studies in Environmental Science, University of Mysore, Mysore, India.
Pradeep S; Department of Biotechnology and Bioinformatics, School of Life Sciences, JSS Academy of Higher Education & Research, Mysuru, Karnataka, India.
Shivamallu C; Department of Biotechnology and Bioinformatics, School of Life Sciences, JSS Academy of Higher Education & Research, Mysuru, Karnataka, India.
Achar RR; Division of Biochemistry, School of Life Sciences, JSS Academy of Higher Education and Research, Mysuru, Karnataka, India.
Silina E; Department of Human Pathology, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.
Stupin V; Department of Hospital Surgery, NI. Pirogov Russian National Research Medical University, Moscow, Russia.
Manturova N; Department of Hospital Surgery, NI. Pirogov Russian National Research Medical University, Moscow, Russia.
Shati AA; Biology Department, Faculty of Science, King Khalid University, Abha, Saudi Arabia.
Alfaifi MY; Biology Department, Faculty of Science, King Khalid University, Abha, Saudi Arabia.
Elbehairi SEI; Biology Department, Faculty of Science, King Khalid University, Abha, Saudi Arabia.
Kollur SP; School of Physical Sciences, Amrita Vishwa Vidyapeetham, Mysuru Campus, Mysuru, Karnataka, India.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2024 Jan 24; Vol. 19 (1), pp. e0296010. Date of Electronic Publication: 2024 Jan 24 (Print Publication: 2024).
Typ publikacji:: Journal Article
MeSH Terms:: Trichoderma*
Erlotinib Hydrochloride ; Molecular Docking Simulation ; Tyrosine Kinase Inhibitors ; ErbB Receptors

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 12.

Tytuł:: Tumor Microenvironment Modulation by Neoadjuvant Erlotinib Therapy and Its Clinical Impact on Operable EGFR-Mutant Non-Small Cell Lung Cancer.
Autorzy:: Ahn BC; Center for Lung Cancer, Division of Hematology and Oncology, Department of Internal Medicine, Research Institute and Hospital, National Cancer Center, Goyang, Korea.
Park C; Research Institute, National Cancer Center, Goyang, Korea.
Kim MS; Center for Lung Cancer, Department of Thoracic Surgery, Research Institute and Hospital, National Cancer Center, Goyang, Korea.
Lee JM; Center for Lung Cancer, Department of Thoracic Surgery, Research Institute and Hospital, National Cancer Center, Goyang, Korea.
Choi JH; Center for Lung Cancer, Department of Thoracic Surgery, Research Institute and Hospital, National Cancer Center, Goyang, Korea.
Kim HY; Department of Radiology, Research Institute and Hospital, National Cancer Center, Goyang, Korea.
Lee GK; Department of Pathology, Research Institute and Hospital, National Cancer Center, Goyang, Korea.
Yu N; Research Institute, National Cancer Center, Goyang, Korea.
Lee Y; Center for Lung Cancer, Division of Hematology and Oncology, Department of Internal Medicine, Research Institute and Hospital, National Cancer Center, Goyang, Korea.
Han JY; Center for Lung Cancer, Division of Hematology and Oncology, Department of Internal Medicine, Research Institute and Hospital, National Cancer Center, Goyang, Korea.; Pokaż więcej
Źródło:: Cancer research and treatment [Cancer Res Treat] 2024 Jan; Vol. 56 (1), pp. 70-80. Date of Electronic Publication: 2023 Jun 21.
Typ publikacji:: Journal Article
MeSH Terms:: Carcinoma, Non-Small-Cell Lung*/drug therapy
Carcinoma, Non-Small-Cell Lung*/genetics
Carcinoma, Non-Small-Cell Lung*/pathology
Lung Neoplasms*/drug therapy
Lung Neoplasms*/genetics
Lung Neoplasms*/pathology
Humans ; Female ; Middle Aged ; Male ; Erlotinib Hydrochloride/adverse effects ; Neoadjuvant Therapy ; Tumor Microenvironment ; Neoplasm Staging ; Hedgehog Proteins/genetics ; Hedgehog Proteins/therapeutic use ; ErbB Receptors/genetics ; Mutation ; Protein Kinase Inhibitors/adverse effects

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 13.

Tytuł:: Recruitment of hexahydroquinoline as anticancer scaffold targeting inhibition of wild and mutants EGFR (EGFR ).
Autorzy:: Abo Al-Hamd MG; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Tanta University, Tanta, Egypt.
Tawfik HO; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Tanta University, Tanta, Egypt.
Abdullah O; Pharmaceutical Chemistry Department, College of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia.
Yamaguchi K; Faculty of Pharmaceutical Sciences, Sojo University, Kumamoto, Japan.
Sugiura M; Faculty of Pharmaceutical Sciences, Sojo University, Kumamoto, Japan.
Mehany ABM; Zoology Department, Faculty of Science, Al-Azhar University, Cairo, Egypt.
El-Hamamsy MH; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Tanta University, Tanta, Egypt.
El-Moselhy TF; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Tanta University, Tanta, Egypt.; Pokaż więcej
Źródło:: Journal of enzyme inhibition and medicinal chemistry [J Enzyme Inhib Med Chem] 2023 Dec; Vol. 38 (1), pp. 2241674.
Typ publikacji:: Journal Article
MeSH Terms:: Antineoplastic Agents*/chemistry
Lung Neoplasms*/drug therapy
Lung Neoplasms*/metabolism
Quinolines*/chemistry
Humans ; Cell Line, Tumor ; Cell Proliferation ; Drug Screening Assays, Antitumor ; ErbB Receptors/metabolism ; Erlotinib Hydrochloride/pharmacology ; Molecular Docking Simulation ; Mutation ; Protein Kinase Inhibitors/chemistry

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 14.

Tytuł:: LMNA Reduced Acquired Resistance to Erlotinib in NSCLC by Reversing the Epithelial-Mesenchymal Transition via the FGFR/MAPK/c-fos Signaling Pathway.
Autorzy:: Hu C; College of Pharmacy (International Academy of Targeted Therapeutics and Innovation), Chongqing University of Arts and Sciences, Chongqing 402160, China.; School of Life Sciences, Chongqing University, Chongqing 401331, China.
Zhou A; College of Pharmacy (International Academy of Targeted Therapeutics and Innovation), Chongqing University of Arts and Sciences, Chongqing 402160, China.
Hu X; College of Pharmacy (International Academy of Targeted Therapeutics and Innovation), Chongqing University of Arts and Sciences, Chongqing 402160, China.
Xiang Y; College of Pharmacy (International Academy of Targeted Therapeutics and Innovation), Chongqing University of Arts and Sciences, Chongqing 402160, China.
Huang M; College of Pharmacy (International Academy of Targeted Therapeutics and Innovation), Chongqing University of Arts and Sciences, Chongqing 402160, China.
Huang J; National & Local Joint Engineering Research Center of Targeted and Innovative Therapeutics, Chongqing University of Arts and Sciences, Chongqing 402160, China.
Yang D; National & Local Joint Engineering Research Center of Targeted and Innovative Therapeutics, Chongqing University of Arts and Sciences, Chongqing 402160, China.
Tang Y; College of Pharmacy (International Academy of Targeted Therapeutics and Innovation), Chongqing University of Arts and Sciences, Chongqing 402160, China.; National & Local Joint Engineering Research Center of Targeted and Innovative Therapeutics, Chongqing University of Arts and Sciences, Chongqing 402160, China.; Pokaż więcej
Źródło:: International journal of molecular sciences [Int J Mol Sci] 2022 Oct 31; Vol. 23 (21). Date of Electronic Publication: 2022 Oct 31.
Typ publikacji:: Journal Article
MeSH Terms:: Carcinoma, Non-Small-Cell Lung*/drug therapy
Carcinoma, Non-Small-Cell Lung*/genetics
Carcinoma, Non-Small-Cell Lung*/metabolism
Epithelial-Mesenchymal Transition*/drug effects
Epithelial-Mesenchymal Transition*/genetics
Erlotinib Hydrochloride*/pharmacology
Lamin Type A*/drug effects
Lamin Type A*/metabolism
Lung Neoplasms*/drug therapy
Lung Neoplasms*/genetics
Lung Neoplasms*/metabolism
Humans ; Cell Line, Tumor ; Drug Resistance, Neoplasm/genetics ; ErbB Receptors/metabolism ; Mutation ; Protein Kinase Inhibitors/pharmacology ; Proto-Oncogene Proteins c-akt/metabolism ; Signal Transduction

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 15.

Tytuł:: Human Blood Serum Can Diminish EGFR-Targeted Inhibition of Squamous Carcinoma Cell Growth through Reactivation of MAPK and EGFR Pathways.
Autorzy:: Kamashev D; I.M. Sechenov First Moscow State Medical University, Moscow 119991, Russia.; Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Moscow 117997, Russia.; Moscow Institute of Physics and Technology, Dolgoprudny 141701, Russia.
Shaban N; Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Moscow 117997, Russia.; Moscow Institute of Physics and Technology, Dolgoprudny 141701, Russia.
Lebedev T; Engelhardt Institute of Molecular Biology, Moscow 119991, Russia.
Prassolov V; Engelhardt Institute of Molecular Biology, Moscow 119991, Russia.
Suntsova M; Moscow Institute of Physics and Technology, Dolgoprudny 141701, Russia.; World-Class Research Center 'Digital Biodesign and Personalized Healthcare', Sechenov First Moscow State Medical University, Moscow 119991, Russia.
Raevskiy M; World-Class Research Center 'Digital Biodesign and Personalized Healthcare', Sechenov First Moscow State Medical University, Moscow 119991, Russia.
Gaifullin N; Department of Pathology, Faculty of Medicine, Lomonosov Moscow State University, Moscow 119992, Russia.
Sekacheva M; World-Class Research Center 'Digital Biodesign and Personalized Healthcare', Sechenov First Moscow State Medical University, Moscow 119991, Russia.
Garazha A; Oncobox Ltd., Moscow 121205, Russia.; Omicsway Corp., Walnut, CA 91789, USA.
Poddubskaya E; World-Class Research Center 'Digital Biodesign and Personalized Healthcare', Sechenov First Moscow State Medical University, Moscow 119991, Russia.
Sorokin M; I.M. Sechenov First Moscow State Medical University, Moscow 119991, Russia.; Moscow Institute of Physics and Technology, Dolgoprudny 141701, Russia.; PathoBiology Group, European Organization for Research and Treatment of Cancer (EORTC), 1200 Brussels, Belgium.
Buzdin A; Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Moscow 117997, Russia.; Moscow Institute of Physics and Technology, Dolgoprudny 141701, Russia.; World-Class Research Center 'Digital Biodesign and Personalized Healthcare', Sechenov First Moscow State Medical University, Moscow 119991, Russia.; PathoBiology Group, European Organization for Research and Treatment of Cancer (EORTC), 1200 Brussels, Belgium.; Pokaż więcej
Źródło:: Cells [Cells] 2023 Aug 08; Vol. 12 (16). Date of Electronic Publication: 2023 Aug 08.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Serum*
Carcinoma, Squamous Cell*/drug therapy
Humans ; Cetuximab/pharmacology ; Cetuximab/therapeutic use ; Epidermal Growth Factor/pharmacology ; Erlotinib Hydrochloride/pharmacology ; Erlotinib Hydrochloride/therapeutic use ; Cell Cycle ; ErbB Receptors

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 16.

Tytuł:: New 1,2,3-Triazole/1,2,4-triazole Hybrids as Aromatase Inhibitors: Design, Synthesis, and Apoptotic Antiproliferative Activity.
Autorzy:: Maghraby MT; Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Assiut University, Assiut 71526, Egypt.; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, New Valley University, New Valley 72511, Egypt.
Mazyad Almutairi T; Department of Chemistry, College of Science, King Saud University, Riyadh 11451, Saudi Arabia.
Bräse S; Institute of Biological and Chemical Systems, IBCS-FMS, Karlsruhe Institute of Technology, 76131 Karlsruhe, Germany.
Salem OIA; Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Assiut University, Assiut 71526, Egypt.
Youssif BGM; Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Assiut University, Assiut 71526, Egypt.
Sheha MM; Department of Medicinal Chemistry, Faculty of Pharmacy, Assiut University, Assiut 71526, Egypt.; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Sphinx University, New-Assiut 71684, Egypt.; Pokaż więcej
Źródło:: Molecules (Basel, Switzerland) [Molecules] 2023 Oct 14; Vol. 28 (20). Date of Electronic Publication: 2023 Oct 14.
Typ publikacji:: Journal Article
MeSH Terms:: Aromatase Inhibitors*/chemistry
Antineoplastic Agents*/chemistry
Aromatase ; Molecular Docking Simulation ; Structure-Activity Relationship ; Erlotinib Hydrochloride/pharmacology ; Cell Line, Tumor ; Triazoles/chemistry ; Cell Proliferation ; Drug Screening Assays, Antitumor ; Molecular Structure

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 17.

Tytuł:: Loss of Key EMT-Regulating miRNAs Highlight the Role of ZEB1 in EGFR Tyrosine Kinase Inhibitor-Resistant NSCLC.
Autorzy:: Gohlke L; Institute of Pharmacy, Clinical Pharmacy, University Greifswald, Friedrich-Ludwig-Jahn-Str. 17, 17489 Greifswald, Germany.
Alahdab A; Institute of Pharmacy, Clinical Pharmacy, University Greifswald, Friedrich-Ludwig-Jahn-Str. 17, 17489 Greifswald, Germany.
Oberhofer A; Munich Biomarker Research Center, Institute of Laboratory Medicine, German Heart Center, Technical University Munich, 80636 Munich, Germany.
Worf K; Munich Biomarker Research Center, Institute of Laboratory Medicine, German Heart Center, Technical University Munich, 80636 Munich, Germany.
Holdenrieder S; Munich Biomarker Research Center, Institute of Laboratory Medicine, German Heart Center, Technical University Munich, 80636 Munich, Germany.
Michaelis M; School of Biosciences, Division of Natural Sciences, University of Kent, Canterbury, Kent CT2 7NJ, UK.
Cinatl J Jr; Institute of Medical Virology, University Hospital Frankfurt, Goethe University, 60596 Frankfurt am Main, Germany.
Ritter CA; Institute of Pharmacy, Clinical Pharmacy, University Greifswald, Friedrich-Ludwig-Jahn-Str. 17, 17489 Greifswald, Germany.; Pokaż więcej
Źródło:: International journal of molecular sciences [Int J Mol Sci] 2023 Sep 29; Vol. 24 (19). Date of Electronic Publication: 2023 Sep 29.
Typ publikacji:: Journal Article
MeSH Terms:: Carcinoma, Non-Small-Cell Lung*/drug therapy
Carcinoma, Non-Small-Cell Lung*/genetics
Carcinoma, Non-Small-Cell Lung*/metabolism
MicroRNAs*/metabolism
Lung Neoplasms*/drug therapy
Lung Neoplasms*/genetics
Lung Neoplasms*/metabolism
Humans ; Tyrosine Kinase Inhibitors ; Erlotinib Hydrochloride/therapeutic use ; Epithelial-Mesenchymal Transition/genetics ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/therapeutic use ; ErbB Receptors/genetics ; ErbB Receptors/metabolism ; Drug Resistance, Neoplasm/genetics ; Cell Line, Tumor ; Mutation ; Zinc Finger E-box-Binding Homeobox 1/genetics

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 18.

Tytuł:: Targeted co-delivery of curcumin and erlotinib by MoS 2 nanosheets for the combination of synergetic chemotherapy and photothermal therapy of lung cancer.
Autorzy:: Chen Z; Institute of Structural Pharmacology & TCM Chemical Biology, College of Pharmacy, Fujian University of Traditional Chinese Medicine, No. 1, Qiuyang Road, Fuzhou, 350122, Fujian, China.
Wei X; Institute of Structural Pharmacology & TCM Chemical Biology, College of Pharmacy, Fujian University of Traditional Chinese Medicine, No. 1, Qiuyang Road, Fuzhou, 350122, Fujian, China.
Zheng Y; Institute of Structural Pharmacology & TCM Chemical Biology, College of Pharmacy, Fujian University of Traditional Chinese Medicine, No. 1, Qiuyang Road, Fuzhou, 350122, Fujian, China.
Zhang Z; Institute of Structural Pharmacology & TCM Chemical Biology, College of Pharmacy, Fujian University of Traditional Chinese Medicine, No. 1, Qiuyang Road, Fuzhou, 350122, Fujian, China.
Gu W; Institute of Structural Pharmacology & TCM Chemical Biology, College of Pharmacy, Fujian University of Traditional Chinese Medicine, No. 1, Qiuyang Road, Fuzhou, 350122, Fujian, China.
Liao W; Key Laboratory of Gastrointestinal Cancer, Ministry of Education, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, 350005, China.
Zhang H; Institute of Structural Pharmacology & TCM Chemical Biology, College of Pharmacy, Fujian University of Traditional Chinese Medicine, No. 1, Qiuyang Road, Fuzhou, 350122, Fujian, China.
Wang X; Institute of Structural Pharmacology & TCM Chemical Biology, College of Pharmacy, Fujian University of Traditional Chinese Medicine, No. 1, Qiuyang Road, Fuzhou, 350122, Fujian, China.
Liu J; Institute of Structural Pharmacology & TCM Chemical Biology, College of Pharmacy, Fujian University of Traditional Chinese Medicine, No. 1, Qiuyang Road, Fuzhou, 350122, Fujian, China. .
Li H; Institute of Structural Pharmacology & TCM Chemical Biology, College of Pharmacy, Fujian University of Traditional Chinese Medicine, No. 1, Qiuyang Road, Fuzhou, 350122, Fujian, China. .
Xu W; Institute of Structural Pharmacology & TCM Chemical Biology, College of Pharmacy, Fujian University of Traditional Chinese Medicine, No. 1, Qiuyang Road, Fuzhou, 350122, Fujian, China. .; Pokaż więcej
Źródło:: Journal of nanobiotechnology [J Nanobiotechnology] 2023 Sep 16; Vol. 21 (1), pp. 333. Date of Electronic Publication: 2023 Sep 16.
Typ publikacji:: Journal Article
MeSH Terms:: Curcumin*/pharmacology
Lung Neoplasms*/drug therapy
Humans ; Erlotinib Hydrochloride/pharmacology ; Photothermal Therapy ; Biotin ; Molybdenum ; Polyethylene Glycols

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 19.

Tytuł:: Gintonin-Induced Wound-Healing-Related Responses Involve Epidermal-Growth-Factor-like Effects in Keratinocytes.
Autorzy:: Won KJ; Department of Physiology and Medical Science, College of Medicine, Konkuk University, Chungju 27478, Republic of Korea.
Lee R; Ginsentology Research Laboratory, Department of Physiology, College of Veterinary Medicine, Konkuk University, Seoul 05029, Republic of Korea.
Choi SH; Department of Animal Health, College of Health and Medical Services, Osan University, Osan 18119, Republic of Korea.
Kim JH; Ginsentology Research Laboratory, Department of Physiology, College of Veterinary Medicine, Konkuk University, Seoul 05029, Republic of Korea.
Hwang SH; Department of Pharmaceutical Engineering, College of Health Sciences, Sangji University, Wonju 26339, Republic of Korea.
Nah SY; Ginsentology Research Laboratory, Department of Physiology, College of Veterinary Medicine, Konkuk University, Seoul 05029, Republic of Korea.; Pokaż więcej
Źródło:: International journal of molecular sciences [Int J Mol Sci] 2023 Sep 14; Vol. 24 (18). Date of Electronic Publication: 2023 Sep 14.
Typ publikacji:: Journal Article
MeSH Terms:: Epidermal Growth Factor*/pharmacology
Keratinocytes*
Erlotinib Hydrochloride ; Heparin-binding EGF-like Growth Factor ; ErbB Receptors

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 20.

Tytuł:: Developing multitarget coumarin based anti-breast cancer agents: synthesis and molecular modeling study.
Autorzy:: Takla FN; Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura, 35516, Egypt.; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Delta University for Science and Technology, International Coastal Road, Gamasa City, 35712, Egypt.
Bayoumi WA; Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura, 35516, Egypt.
El-Messery SM; Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura, 35516, Egypt. .
Nasr MNA; Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura, 35516, Egypt.; Pokaż więcej
Źródło:: Scientific reports [Sci Rep] 2023 Aug 17; Vol. 13 (1), pp. 13370. Date of Electronic Publication: 2023 Aug 17.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Antineoplastic Agents*/pharmacology
Neoplasms*
Erlotinib Hydrochloride/pharmacology ; Doxorubicin ; Aromatase Inhibitors ; Coumarins/pharmacology

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Informacja

Wyszukujesz frazę ""Erlotinib Hydrochloride"" wg kryterium: Temat

Źródło danych

Ogranicz do:

Ogranicz do bazy

Typ dokumentu

Temat

Wydawca

Publikacja

Język